Cargando…
Efficacy and safety of sodium zirconium cyclosilicate in patients with baseline serum potassium level ≥ 5.5 mmol/L: pooled analysis from two phase 3 trials
BACKGROUND: Reliable, timely-onset, oral treatments with an acceptable safety profile for patients with hyperkalemia are needed. We examined the efficacy and safety of sodium zirconium cyclosilicate (SZC; formerly ZS-9) treatment for ≤ 48 h in patients with baseline serum potassium level ≥ 5.5 mmol/...
Autores principales: | Amin, Alpesh N., Menoyo, Jose, Singh, Bhupinder, Kim, Christopher S. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6889520/ https://www.ncbi.nlm.nih.gov/pubmed/31791288 http://dx.doi.org/10.1186/s12882-019-1611-8 |
Ejemplares similares
-
Effects of sodium zirconium cyclosilicate on sodium and potassium excretion in healthy adults: a Phase 1 study
por: Någård, Mats, et al.
Publicado: (2020) -
Potassium reduction with sodium zirconium cyclosilicate in patients with heart failure
por: Tardif, Jean‐Claude, et al.
Publicado: (2022) -
Sodium zirconium cyclosilicate (ZS-9) treatment in patients with serum potassium >6.5 mEq/L
por: Rasmussen, Henrik
Publicado: (2015) -
Sodium Zirconium Cyclosilicate: A Review in Hyperkalaemia
por: Hoy, Sheridan M.
Publicado: (2018) -
Correction to: Sodium Zirconium Cyclosilicate: A Review in Hyperkalaemia
por: Hoy, Sheridan M.
Publicado: (2019)